SPEX Stock Overview
A clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Spexis AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.05 |
| 52 Week High | CHF 1.06 |
| 52 Week Low | CHF 0.03 |
| Beta | 0.25 |
| 11 Month Change | 0% |
| 3 Month Change | 11.11% |
| 1 Year Change | 11.11% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPEX | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 150.0% | -11.1% | -1.4% |
| 1Y | 11.1% | 103.0% | 4.8% |
Return vs Industry: SPEX underperformed the Swiss Biotechs industry which returned 92.6% over the past year.
Return vs Market: SPEX exceeded the Swiss Market which returned 5.2% over the past year.
Price Volatility
| SPEX volatility | |
|---|---|
| SPEX Average Weekly Movement | 166.7% |
| Biotechs Industry Average Movement | 12.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: SPEX's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: SPEX's weekly volatility has increased from 93% to 167% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | Jeff Wager | spexisbio.com |
Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis AG is headquartered in Allschwil, Switzerland.
Spexis AG Fundamentals Summary
| SPEX fundamental statistics | |
|---|---|
| Market cap | CHF 2.03m |
| Earnings (TTM) | -CHF 19.62m |
| Revenue (TTM) | CHF 595.35k |
5.7x
P/S Ratio-0.2x
P/E RatioIs SPEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPEX income statement (TTM) | |
|---|---|
| Revenue | CHF 595.35k |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 595.35k |
| Other Expenses | CHF 20.21m |
| Earnings | -CHF 19.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,295.35% |
| Debt/Equity Ratio | 222.4% |
How did SPEX perform over the long term?
See historical performance and comparison